NCT03855189

Safety and Efficacy of Mometasone Furoate (SCH 032088) vs Beclomethasone Dipropionate or Placebo in Seasonal Allergic Rhinitis (C93-013)

Safety and Efficacy of SCH 32088 vs Beclomethasone Dipropionate (Vancenase AQ) and Placebo in Seasonal Allergic Rhinitis

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 345 (actual)
• Sponsor: Organon and Co · Industry
• Sex: All
• Age: 12 Years
• Healthy volunteers: Not accepted

Summary

The objectives of this study are to determine the safety and efficacy in seasonal allergic rhinitis of a four-week course of mometasone furoate compared to beclomethasone dipropionate or placebo.

Conditions

• Seasonal Allergic Rhinitis

Interventions

Type	Name	Description
DRUG	Mometasone Furoate (MF)	Mometasone furoate nasal spray administered as 200 mcg total dose per day for 4 weeks.
DRUG	Beclomethasone Dipropionate (BDP)	Beclomethasone dipropionate nasal spray administered as 168 mcg twice daily (BID) \[336 mcg total dose per day\] for 4 weeks.
DRUG	Placebo	Placebo nasal spray administered for 4 weeks.

Timeline

• Start date: 1993-08-23
• Primary completion: 1993-10-08
• Completion: 1993-10-22
• First posted: 2019-02-26
• Last updated: 2022-02-09
• Results posted: 2019-08-09